Slide 1: Full Year and Q4 2024 Results
Full Year and Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025
Slide 2: Forward-looking statements
Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures.
Slide 3: Conference call agenda
Q4 and FY 2024 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Haematology Business EVP, Oncology Haematology R&D BioPharmaceuticals Ruud Dobber S
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Remarkable execution across key fundamentals in FY 2024
Remarkable execution across key fundamentals in FY 2024 +21% Total Revenue (vs FY 2023) Delivered on upgraded FY 2024 financial guidance +19% Core EPS (vs FY 2023) +14% OpEx (vs FY 2023) 9 positive high-value Phase III Multiple blockbuster opportunities trial readouts in 20241 with combined PYR >$5b
Slide 6: FY 2024 – strong global growth across focus therapy areas
FY 2024 – strong global growth across focus therapy areas +24% Broad-based, diverse source +21% V&I: 1,462 +8% of Total Revenue R&I: 7,876 +25% Strength across FY 2024 | % Total Revenue by therapy area therapy areas CVRM: 12,517 +16% V&I Other FY 2024 | Total Revenue +20% Oncology CVRM R&I Rare Dise
Slide 7: Sustained, durable growth across Emerging Markets
Sustained, durable growth across Emerging Markets Accelerating Emerging Markets growth1 Emerging Markets – 67% of global population2 22% 20% 16% Healthcare expenditure increasing and access improving3 10% AstraZeneca sustained presence is a competitive FY 2021 FY 2022 FY 2023 FY 2024 Emerging Market
Slide 8: Entering remarkably catalyst-rich 2025
Entering remarkably catalyst-rich 2025 Key indication expansion opportunities in high-value tumour types or diseases H1 2025 eneboparatide | hypoPT Breast cancer Enhertu Datroway camizestrant | HR+/HER2- BC HER2+ 1L and early-stage 1L TNBC ceralasertib | post-IO NSCLC Lung cancer Datroway 1L NSQ/NSQ
Slide 9: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER
Slide 10: FY and Q4 2024 – Reported profit and loss
FY and Q4 2024 – Reported profit and loss FY 2024 CER change % Total Q4 2024 CER change % Total $m % Revenue $m % Revenue Total Revenue 54,073 21 100 14,891 25 100 - Product Sales 50,938 19 94 13,362 19 90 - Alliance Revenue 2,212 55 4 714 69 5 - Collaboration Revenue 923 54 2 815 >2x 5 Product Sale
Slide 11: FY and Q4 2024 – Core profit and loss
FY and Q4 2024 – Core profit and loss FY 2024 CER change % Total Q4 2024 CER change % Total $m % Revenue $m % Revenue Total Revenue 54,073 21 100 14,891 25 100 - Product Sales 50,938 19 94 13,362 19 90 - Alliance Revenue 2,212 55 4 714 69 5 - Collaboration Revenue 923 54 2 815 2x 5 Product Sales Gro
Slide 12: FY 2025 guidance
FY 2025 guidance Net cash inflow from operating activities increased by 15% in 2024 Net debt/Adjusted EBITDA 1.5x FY 2025 guidance (CER) $bn 0.1 4.6 Total Revenue anticipated to increase by a high single-digit percentage 11.9 7.0 24.6 Core EPS 22.5 2.2 anticipated to increase by a low double-digit p
Slide 13: Diverse global manufacturing footprint
Diverse global manufacturing footprint CapEx investment to support sustained long-term growth Södertälje, Sweden Existing site Biologics filling capabilities Legend New site Increasing Dublin, Ireland investment New API facility Rockville, Maryland Next-generation cell therapy manufacturing Coppell,
Slide 14: Oncology
Oncology Dave Fredrickson ONCOLOGY HAEMATOLOGY BUSINESS Susan Galbraith ONCOLOGY HAEMATOLOGY R&D
Slide 15: Oncology – FY and Q4 2024
Oncology – FY and Q4 2024 Multiple medicines achieved new multi-blockbuster levels in FY 2024 Oncology FY 2024 $22.4bn, +24% Q4 2024: key dynamics 7,000 • Tagrisso +21%, strong demand across indications, partly offset by hospital 6,000 ordering dynamic in CN • Calquence +20%, sustained BTKi leadersh
Slide 16: Oncology – key drivers in 2025
Oncology – key drivers in 2025 Strong Tagrisso, Enhertu, Imfinzi growth momentum STRATEGIC EXPANSION Ongoing trials build on Tagrisso as • Market leader in 1L, sustained FLAURA-2 growth backbone in EGFRm • Continued early-stage adoption with ADAURA, LAURA SAFFRON | TROPION-Lung14, -15 • DESTINY-Brea
Slide 17: Oncology – select Phase III readouts in 2025
Oncology – select Phase III readouts in 2025 Indication expansion and NME Phase III trials expand ambition in key tumour types camizestrant potential best-in-class next generation SERD with differentiated programme in HR+ HER2- breast cancer AVANZAR (NSCLC) TROPION-Breast02 (TNBC) — Improved PFS vs.
Slide 18: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D
Slide 19: BioPharmaceuticals – FY and Q4 2024
BioPharmaceuticals – FY and Q4 2024 Total Revenue $21.9bn, +21%, strong momentum from multiple medicines CVRM R&I Q4 2024: key dynamics FY 2024 $12.5bn, +20% FY 2024 $7.9bn, +25% 3,500 2,500 • Farxiga +22%, global demand growth 3,000 • Lokelma +35%, market share leadership 2,000 2,500 • Fasenra +12%
Slide 20: BioPharma – key growth drivers in 2025
BioPharma – key growth drivers in 2025 Significant potential as more patients move onto guideline-based therapies STRATEGIC EXPANSION • Guidelines continue to drive SGLT2i class expansion Farxiga provides foundation for • Continued growth despite anticipated China VBP dapagliflozin FDCs in developme
Slide 21: BioPharma – select Phase III readouts in 2025
BioPharma – select Phase III readouts in 2025 Meaningful indication expansion and high-value NME opportunity Strengthening industry-leading COPD and asthma baxdrostat potential best-in-class novel medicine for the portfolio with indication expansion opportunities treatment of hard-to-treat hypertens
Slide 22: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION
Slide 23: Rare Disease – FY and Q4 2024
Rare Disease – FY and Q4 2024 Total Revenue +16% in 2024 driven by growing demand for key medicines Rare Disease FY 2024 Total Revenues $8.8bn, +16% Q4 2024: key dynamics 2,500 C5 Franchise: continued sustainable growth 2,000 • Ultomiris +33%, driven by demand growth in neurology indications (gMG, N
Slide 24: Rare Disease – key growth drivers in 2025
Rare Disease – key growth drivers in 2025 Increasing momentum with Ultomiris, Strensiq and Koselugo STRATEGIC EXPANSION • Continued growth in neurology indications driven by new Indication expansion to unlock to branded medicines and Soliris switch patients new growth opportunities • Launches in new
Slide 25: Rare disease – Phase III readouts in 2025
Rare disease – Phase III readouts in 2025 First Phase III data for 4 potential NMEs ACCELERATED ACCELERATED eneboparatide anselamimab efzimfotase alfa gefurulimab Ultomiris CALYPSO | HypoPT CAEL-301/2 | AL-A HICKORY/CHESTNUT | HPP PREVAIL | gMG TMA-313/4 | HSCT-TMA PTH1 receptor Enzyme replacement N
Slide 26: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 27: 2025 outlook supports delivery of strategic ambitions
2025 outlook supports delivery of strategic ambitions Sustained commercial Broad-based global momentum Pipeline execution business • Growing demand for • Growth momentum across key medicines substantially offsets • First Phase III data for 7 NMEs regions, notably US IRA and China VBP • Multiple high
Slide 28: Significant progress with transformative technologies to drive 2030+ growth
Significant progress with transformative technologies to drive 2030+ growth Weight management ADCs and Cell therapy and Gene therapy and Next-gen IO bispecifics and risk factors Radioconjugates T-cell engagers gene editing Establish and Develop scalable cell Replace systemic Make cure possible lead
Slide 29: On track to deliver on 2030 ambitions supported by strong momentum
On track to deliver on 2030 ambitions supported by strong momentum and catalyst-rich 2025 Ambition to deliver $80bn in On track to deliver mid-30s% Ambition to deliver at least 20 Total Revenue by 20301 Core operating margin by 2026 NMEs by 2030 Strong growth in 2025 with global Growth in SG&A slowe
Slide 30: Appendix
Appendix
Slide 31: Appendix – high-value positive Phase III trials in 2024
Appendix – 9 high-value positive Phase III trials in 2024 LAURA | Stg III u/r NSCLC ADRIATIC | LS-SCLC Expanding Tagrisso as backbone TKI in Imfinzi first and only IO to show survival benefit in LS-SCLC early-stage NSCLC ECHO | MCL NIAGARA | MIBC Imfinzi first perioperative IO regimen to extend surv
Slide 32: Appendix – entering remarkably catalyst-rich 2025
Appendix – entering remarkably catalyst-rich 2025 Multiple indication expansion opportunities for existing medicines and first Phase III data for 7 NMEs Select Phase III data for existing medicines First Phase III data for NMEs Datroway | lung and breast cancer camizestrant SERENA-6 (HR+/HER2- mBC)
Slide 33: Appendix – AstraZeneca P&L reference table
Appendix – AstraZeneca P&L reference table P&L line-item definitions P&L line-item definition Product Sales • Recognises sales from territories where Group has lead commercialisation • Recognises supply of Beyfortus to Sanofi Alliance Revenue • Alliance Revenue comprises income arising from the ongo
Slide 34: Oncology – Tagrisso and Lynparza revenue
AP P E ND I X | Total Revenue Performance Oncology Tagrisso Lynparza (Product Sales) 16% growth at CER to $6,580m in FY 2024 11% growth at CER to $3,072m in FY 2024 900 1,800 800 1,600 700 1,400 600 1,200 Product Sales ($m) Total Revenue ($m) 1,000 500 800 400 600 300 400 200 200 100 0 0 Q4 Q1 Q2 Q3
Slide 35: Oncology – Imfinzi and Imjudo revenue
AP P E ND I X | Total Revenue Performance Oncology Imfinzi Imjudo 21% growth at CER to $4,717m in FY 2024 31% growth at CER to $281m in FY 2024 1,400 80 70 1,200 60 1,000 Total Revenue ($m) 50 Total Revenue ($m) 800 40 600 30 400 20 200 10 0 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 20
Slide 36: Oncology – Calquence and Enhertu revenue
AP P E ND I X | Total Revenue Performance Oncology Calquence Enhertu 25% growth at CER to $3,129m in FY 2024 58% growth at CER to $1,982m in FY 2024 900 600 800 500 700 600 400 Total Revenue ($m) Total Revenue ($m) 500 300 400 300 200 200 100 100 0 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 37: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
AP P E ND I X | Total Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 31% growth at CER to $7,717m in FY 2024 2% growth at CER to $1,333m in FY 2024 34% growth at CER to $542m in FY 2024 2,500 400 160 350 140 2,000 300 120 Total Revenue ($m) Total
Slide 38: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | Total Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Breztri Tezspire 9% growth at CER to $1,689m in FY 2024 46% growth at CER to $978m in FY 2024 2x growth at CER to $684m in FY 2024 500 300 250 450 250 400 200 350 200 Total Revenue ($m) Total Revenue ($m)
Slide 39: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | Total Revenue Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Pulmicort 25% growth at CER to $2,879m in FY 2024 1% decrease at CER to $682m in FY 2024 900 250 800 700 200 600 Total Revenue ($m) Total Revenue ($m) 150 500 400 100 300 200 50 100 0 0 Q4 Q1 Q2 Q3 Q4 Q1
Slide 40: Rare Disease
AP P E ND I X | Total Revenue Performance Rare Disease Ultomiris Strensiq Koselugo (Product Sales) 34% growth at CER to $3,924m in FY 2024 24% growth at CER to $1,416m in FY 2024 66% growth at CER to $531m in FY 2024 1,200 450 180 400 160 1,000 350 140 800 300 120 Product Sales ($m) Total Revenue ($
Slide 41: Glossary
Glossary 1L, 2L, 3L first-, second-, third-line ESR1m estrogen receptor alpha-mutated NMOSD neuromyelitis optica spectrum disorder AAV adeno-associated virus ET endocrine therapy NRDL national reimbursement drug list abema abemaciclib EU Europe NSCLC non-small cell lung cancer ACC American College o
Slide 42: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis